Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527520) titled 'Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial' on April 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fudan University
Condition:
Rectal Cancer
Moderately Hypofractionated Radiotherapy
Serplulimab
pMMR/MSS
Intervention:
Radiation: Moderately Hypofractionated Radiotherapy
Drug: Serplulimab
Recruitment Status: N...